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Abstract Borderline ovarian tumors (BOT) are uncommon
but not rare epithelial ovarian neoplasms, intermediate between
benign and malignant categories. Since BOT were first identi-
fied >40 years ago, they have inspired controversies dispropor-
tionate to their incidence. This review discusses diagnostic
criteria for the histologic subtypes of BOT, highlighting areas
of diagnostic challenges, ongoing controversies, and changes in
terminology implemented by the recent 2014 WHO
Classification of Tumours of the Female Genital Organs.
Emerging knowledge supports the notion that subtypes of bor-
derline ovarian tumors comprise distinct biologic, pathogenetic,
and molecular entities, precluding a single unifying concept for
BOT. Serous borderline tumors (SBT) share molecular and
genetic alterations with low-grade serous carcinomas and can
present at higher stages with peritoneal implants and/or lymph
node involvement, which validates their borderline malignant
potential. All other (non-serous) subtypes of BOT commonly
present at stage I confined to the ovary(ies) and are associated
with overall survival approaching that of the general
population. An important change in the WHO 2014 classifica-
tion is the new terminology of non-invasive implants associated
with SBT, as any invasive foci (previously called “invasive
implants”) are now in line with their biological behavior con-
sidered peritoneal low-grade serous carcinoma (LGSC). The
controversy regarding the terminology of non-serous borderline
tumors, called by some pathologists “atypical proliferative tu-
mor” in view of their largely benign behavior, has not been
resolved. The concepts of intraepithelial carcinoma and
microinvasion may evolve in further studies, as their presence
appears to have no prognostic impact and is subject to consid-
erable inter-observer variability.
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Introduction
Borderline ovarian tumors (BOT) are neoplasms of epithelial
origin characterized by up-regulated cellular proliferation and
the presence of slight nuclear atypia but without destructive
stromal invasion [1]. This group of tumors was first described
by Taylor in 1929 as “semi-malignant” ovarian tumors with
peritoneal involvement but surprisingly good prognosis and
subsequently recognized by the International Federation of
Gynecology and Obstetrics (FIGO) in 1971 as tumors of
“low malignant potential” distinct from ovarian carcinomas
[2] followed by the WHO in 1973 [3]. The current 2014
WHO Classification of Tumours of the Female Genital
Organs uses the term “borderline tumor” interchangeable with
“atypical proliferative tumor”—a terminology that was dis-
couraged in the previous WHO classification [4], whereas
the previously advocated synonym “tumor of low malignant
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Six histologic subtypes of BOT are distinguished based on
the epithelial cell type, similar to invasive carcinomas, com-
prising serous (50%) and mucinous (45%), and less common
subtypes including endometrioid, clear cell, seromucinous,
and borderline Brenner tumor [1, 6]. Although the distinction
of serous or mucinous BOT from frankly malignant tumors
with destructive stromal invasion does not usually pose a di-
agnostic problem, BOTcan be associated with microinvasion,
intraepithelial carcinoma, lymph node involvement, and non-
invasive peritoneal implants [7] and establishing the correct
diagnosis can be challenging in these cases. The diagnostic
criteria are less well defined for the uncommon histologic
subtypes and sometimes hampered by subjectivity. The dis-
tinction of BOT from its benign adenomatous counterparts is
equally important, and overdiagnosis should be avoided, since
it has important clinical implications regarding staging and
follow-up. A workshop sponsored by the National Institutes
of Health Office of Rare Diseases in 2003 provided consensus
for many of the currently accepted criteria defining various
aspects of BOT [1].
The vast majority of BOT are limited to the ovary(ies) at
presentation with 75% being diagnosed at FIGO stage I, com-
pared to only 10% of ovarian carcinomas diagnosed at an
early stage. They generally have an excellent prognosis with
a 10-year survival of 97% for all stages combined [8–10],
although recurrences and malignant transformation can occur.
Standard treatment includes complete surgical resection and
surgical staging including omentectomy, peritoneal biopsies,
cytology of peritoneal washings, and appendectomy in case of
mucinous BOT [10, 11]. Adjuvant chemotherapy is not indi-
cated [12, 13].
This review summarizes pertinent diagnostic criteria for all
six different histologic subtypes of BOT, with particular em-
phasis on areas of ongoing controversy and changes imple-
mented by the recent WHO 2014 classification compared to
previous classifications.
Serous borderline tumor
Approximately 50–55% of BOT belong to this subtype (syn-
onymous “atypical proliferative serous tumor”) [5]. Molecular
analyses have demonstrated that serous borderline tumors
(SBTs) harbor similar molecular and genetic alterations as
low-grade serous carcinomas (LGSC) [14–17]. In some cases,
a continuous tumor progression from cystadenomas and BOT
to low-grade carcinomas may exist, and co-existing areas of
SBT were observed in 30 out of 50 LGSC in a series by
Malpica et al. [18]. KRAS and BRAF mutations are each
present in about 30% of SBT, usually in a mutually exclusive
fashion [14, 19–21]. In contrast, p53 mutations are almost
exclusively found in high-grade serous ovarian carcinomas
[15, 22]. While the fallopian tube has been established as the
site of origin for some high-grade serous carcinomas, SBTs
were historically presumed to originate in the ovarian cortex
or peritoneal surface. Recent reports showing a higher fre-
quency of PAX2-negative secretory cell outgrowths
(SCOUT) in the fallopian tubes of women with SBT may
warrant further study [23].
On gross pathologic examination, SBTs are unilocular or
multilocular cystic tumors with or without epithelial prolifer-
ations on the outer tumor surface. About one third of SBTs are
bilateral. The histology of BOT is characterized by hierarchi-
cally branching papillae and pseudopapillae with
paucicellular, edematous, or hyalinized fibrous stroma, lined
by architecturally complex epithelial proliferations (Fig. 1a).
The epithelial cells are typically columnar, resembling secre-
tory cells of the fallopian tube, admixed with variable numbers
of ciliated cells. There is mild to moderate nuclear atypia,
hyperchromasia, epithelial multilayering, and cell detachment
(“tufting”) into the lumen [6, 24] (Fig. 1b). Most authors,
including the WHO 2014 classification, agree that >10% bor-
derline histology within a cystadenoma or cystadenofibroma
qualifies as BOT. In contrast, serous cystadenomas with foci
qualifying as SBT in <10% of the epithelial volume are des-
ignated “cystadenoma/fibroma with focal epithelial prolifera-
tion” [1, 25] [5]. By immunohistochemistry, SBTs are charac-
terized by expression of WT1, PAX8, Bcl-2, estrogen and
progesterone receptor [26–28].
A recent retrospective study by the authors demonstrated
that overdiagnosis of cystadenoma/fibroma as SBT has been a
relevant clinical problem in the past, albeit in a low percentage
of cases. Out of 81 consecutive cases diagnosed as BOTover a
10-year period at a single tertiary center (1998–2008), the
diagnosis of SBT was rejected due to a diagnosis of serous
cystadenoma/fibroma in 7 (9%) patients [29]. This cohort of
81 patients was part of a larger multicenter study, which con-
firmed that an overdiagnosis of borderline tumor had been
made in 11.5% (92/803) of patients [30].
Microinvasion
The term “microinvasion” has been refined in the recentWHO
2014 classification and is now limited to isolated rounded
eosinophilic cells or cell clusters within the stroma, with a
cytomorphology resembling the epithelial cells lining the sur-
face of the papillae. Microinvasive foci are often surrounded
by retraction spaces and a stroma rich in fibroblasts and cannot
exceed 5 mm in the largest linear dimension [5, 25, 31, 32]
(Fig. 1f). In contrast, solid nests or cribriform glands cytolog-
ically resembling low-grade serous carcinoma, previously al-
so classified as microinvasion when measuring <5 mm, are
now designated LGSC regardless of their size. These small
invasive carcinomas may be diagnosed as “microinvasive car-
cinoma” [5] and are characteristically surrounded by
desmoplastic stroma with abundant collagenous extracellular
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matrix without significant inflammation or fibroblast
proliferation.
The nature of epithelial cells in microinvasive foci has only
recently been started to be elucidated. Kurman’s group
demonstrated a lower intensity of WT1, as well as estrogen
and progesterone receptor expression, and a lower Ki67 index
in microinvasive foci compared to the columnar/cuboidal tu-
mor cells covering the papillary surfaces in 37 patients with
Fig. 1 SBTwith hierarchically branched papillae (a) covered by a single-
layered or multilayered epithelium with pseudopapillary proliferations
and secretory or ciliated serous differentiation (b). Micropapillary SBT
demonstrates non-hierarchical “Medusa-like” branching and a more
cellular stroma (c). Its epithelium is more cuboidal with “nuclear atypia
greater than that allowed for conventional SBT” and often containing
small nucleoli (d). Some micropapillary SBTs have a predominant
cribriform epithelial proliferation (e). Microinvasion is characterized by
small epithelial cell groups surrounded by retraction artifacts within a
cell-rich fibroblastic stroma (f)
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SBT. Together with morphologic evidence of apoptosis, these
findings suggest terminal differentiation and/or senescence in
microinvasive cells [33]. Nevertheless, this does not fully ex-
plain why these cells become entrapped within stroma. In
addition, a higher rate of microinvasion has been observed
in SBT diagnosed during pregnancy [32, 34], suggesting pos-
sible influence by hormonal factors.
Microinvasion has not been consistently associated with an
adverse prognostic effect [6, 34, 35]. A previous study evalu-
ating various patterns of stromal-epithelial invasion not meet-
ing the criteria for classic destructive invasion in a series of 60
SBT (FIGO I-III) found that neither size of the largest invasive
aggregate (1–12 mmmaximum dimension) nor extent of stro-
mal involvement and number of microinvasive foci correlated
with outcome [34]. In a meta-analysis [36], both
micropapillary pattern and microinvasion were associated
with higher recurrence rates (36%; 92/255 and 23%; 47/203,
respectively) although it is not documented how many of
these cases were associated with invasive peritoneal disease
(LGSC, previously designated “invasive implants”). Other re-
cent studies found no association of microinvasion with recur-
rence rate or survival [37, 38].
SBT—micropapillary variant
The micropapillary variant of SBT is now mentioned as a
distinct subtype of SBT in the recent WHO classification,
comprising 5–15% of SBT in different series [30, 39, 40].
This SBT variant was initially described as “non-invasive
low-grade serous carcinoma” (non-invasive LGSC) by
Kurman [39, 40], and this term has been adopted as synony-
mous with “SBT—micropapillary variant” in the current
WHO classification [5]. The architectural criteria for its diag-
nosis have not changed. Micropapillary SBT is characterized
by the lack of hierarchically branching papillae, showing ei-
ther elongate filiform “micropapillae” (≥5:1 length to width
ratio) or cribriform epithelium lining the cyst walls or large-
caliber fibrovascular papillae, with at least one area of contin-
uous micropapillary or cribriform growth >5 mm in one di-
mension [6, 25, 39, 40] (Fig. 1c to e). The stroma of
micropapillary SBT is characterized by a higher fibroblast den-
sity compared to conventional SBT. In contrast to the previous
WHOclassification, additional cytologic criteria have been stated
for the diagnosis of micropapillary SBT requiring “nuclear atypia
greater than that allowed in SBT” typically characterized by
rounded cells with lack of cilia, high nuclear to cytoplasmic ratio,
and often small but prominent cherry-red nucleoli. SBT with a
micropapillary pattern not meeting these diagnostic criteria (size
>5 mm and increased cytologic atypia) should be classified
“SBTwith focal micropapillary features” [5].
The biologic nature of the micropapillary variant of SBTand
its relation to conventional SBT and invasive LGSC, respec-
tively, remains controversial. Kurman suggested the
micropapillary variant of SBT as an intermediate entity in the
progression from SBT to LGSC [17]. Gene expression analysis
performed on laser-microdissected tumor cells from 37 cases of
conventional SBT (n = 17), micropapillary variant of SBT
(n = 9), and LGSC (n = 11) support this view, demonstrating
differential gene expression patterns between SBT and its
micropapillary variant, but no differences in gene expression
between micropapillary SBT and LGSC [41]. All three entities
are genomically relatively stable, and LGSC demonstrated only
marginally increased chromosomal aberrations compared to
SBT and the micropapillary variant of SBT [42–47].
A micropapillary pattern alone is no independent prognostic
factor [6, 7], and only those cases associated with invasive peri-
toneal disease (LGSC, previously designated invasive implants)
showed shorter disease-free and overall survival [37, 48, 49]. The
largest nationwide cohort of SBTwith central pathology review
included 1487 women diagnosed with SBT or micropapillary
variant of SBT in Denmark over a 25-year period (1978–2002)
[50]. This study demonstrated that the overall survival of women
with tumor confined to the ovaries (FIGO stage I) is not different
from the general population. Overall survival was only reduced
in women with advanced stages, and this applied to both women
with SBT and the micropapillary variant of SBT [50]. However,
the micropapillary variant of SBT more frequently presented at
advanced stages compared to conventional SBT (27 versus 13%)
and was more frequently associated with invasive peritoneal dis-
ease [50]. Conflicting data exist regarding the recurrence risk
associated with the micropapillary variant of SBT. While some
studies reported higher recurrence rates [51, 52], others including
the largest multicenter study of BOT to date with 950 patients
found no association with recurrence risk [7, 30, 37, 48].
The current clinical management of themicropapillary variant
of SBT does not differ from conventional SBT. For histopatho-
logic assessment of micropapillary SBT, thorough sampling is
critical and particularly extra-ovarian lesions should be assessed
for the possible presence of invasive disease (LGSC).
Low-grade serous carcinoma
The most important differential diagnosis of all SBTs is inva-
sive LGSC. As mentioned in the previous section, the
cytomorphology of LGSC is identical to the micropapillary
variant of SBT (syn. non-invasive LGSC) and thus is not a
discriminating criterion. Architecture and stroma, however, dif-
fer with a cell-rich, micropapillary or tubulus-like epithelial
proliferation embedded in a collagenous, often hyalinized ma-
trix with only scant fibroblasts and no significant inflammation.
Implants of SBT
Approximately one third of SBTs are associated with peritoneal
implants [7, 30, 53]. The prior subdivision of non-invasive and
invasive implants has been abandoned in the recent WHO
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classification, and any invasive foci are now considered perito-
neal LGSC reflecting their similar biologic behavior [5].
Implants consist of serous epithelial proliferations on the peri-
toneal surface or in peritoneal invaginations, showing either (I)
branching papillae covered by serous epithelial cells surrounded
by a glomerulus-like small cyst and a calretinin-positive cell rim
without a stromal response (previously called epithelial implant)
or (II) tubular glands, small nests, and single eosinophilic cells
within a desmoplastic inflamed “granulation tissue-type” stroma
(previously called desmoplastic implant). Since both types of
implants frequently occur together and their subclassification
has no prognostic relevance, they are collectively designated
“implants” in the WHO 2014 classification. By definition, im-
plants are confined to the peritoneal surfacewithout infiltration of
the underlying subperitoneal fat. Of note, omental implants lim-
ited to the peritoneal surface can result in merging of lobular
clefts, thereby imitating an infiltrative growth pattern [6, 25, 40].
In contrast, peritoneal lesions characterized by an extensive
epithelial component with haphazardly arranged glands, solid
nests, and/or papillary structures accompanied by desmoplastic
stroma with little or no inflammation and with invasion of un-
derlying subperitoneal tissue or omental fat were classified in-
vasive implants in the previous WHO classification. The cur-
rent WHO 2014 classification now designates these foci as
LGSC. In addition, implants lacking an infiltrative growth but
displaying other features suggestive of LGSC, particularly a
micropapillary or cribriform growth pattern and clear retraction
spaces, should also be designated LGSC.
This new nomenclature of extra-ovarian invasive disease is
supported by studies demonstrating their similar biologic be-
havior and disease progression compared to LGSC [7, 54].
Nevertheless, the volume of invasive disease may have prog-
nostic impact. Future studies are needed to clarify the long-
term outcome of ovarian SBT associated with small foci of
invasive peritoneal disease (LGSC) compared to primary
ovarian/peritoneal LGSC presenting with widespread perito-
neal carcinomatosis and bulky disease. The size of invasive
foci should be stated in the pathology report.
Most studies reported no adverse prognosis for (non-
invasive) implants, whereas invasive peritoneal disease
(LGSC) was associated with shorter overall survival [12, 25,
55] [7]. In a meta-analysis of 97 studies including 4129 pa-
tients with SBT, Seidman et al. reported an overall survival of
virtually 100% for stage I tumors and 95.3% for advanced
stage tumors with (non-invasive) implants, whereas survival
for tumors associated with invasive peritoneal disease (LGSC)
was reduced to 66%. The presence of a micropapillary variant
of SBT was a strong predictor for concurrent invasive perito-
neal disease (LGSC) [7].
Lymph nodes may also contain foci of SBT similar to their
peritoneal counterparts, with individual or clusters of serous
epithelial cells with intense eosinophilic cytoplasm located
within sinuses, most commonly in subcapsular location.
These intrasinusoidal cells have recently been shown to dis-
play a senescent phenotype, similar to the epithelial cells of
microinvasive foci, and have no prognostic effect [33]. Rarely,
foci of LGSC with associated desmoplasia and destruction of
lymph node architecture have been reported in patients with
ovarian SBT and should be classified as LGSC [5].
According to both UICC and FIGO classification, the T-
stage is affected by the presence of peritoneal implants, similar
to the staging of invasive carcinoma [56]. In contrast, lymph
node involvement by SBT is not considered metastatic disease
and classified as pN0, and the benign nature of these lesions
should be mentioned in the pathology report [5].
Mucinous borderline tumor
Mucinous borderline tumors (synonymous atypical proliferative
mucinous tumors) are the second most common type and ac-
count for about 35 to 45% of ovarian borderline tumors [5].
These tumors are usually large, unilateral, and cystic with a
smooth ovarian surface, composed of multiple cystic spaces with
variable diameter. The cysts are lined by columnar mucinous
epithelium of gastric or intestinal differentiation, with papillary
or pseudopapillary infoldings, and admixed goblet cells and neu-
roendocrine cells [57] (Fig. 2a). The nuclei are basally located,
isomorphic, and with evenly distributed chromatin [58, 59] (Fig.
2b). Mucinous cystadenomas are characterized by a similar mu-
cinous epithelium but lack papillary infoldings. At least 10% of
the epithelial volume must demonstrate increased proliferation
with papillary infoldings or pseudostratification andmild tomod-
erate nuclear atypia to qualify as mucinous borderline tumor
(MBT)). Immunohistochemically, MBTs are characterized by
their non-Mullerian differentiation with absence of WT1, estro-
gen and progesterone receptor expression [60, 61]. Most tumors
demonstrate diffuse expression of cytokeratin 7 with patchy co-
expression of cytokeratin 20 and variable (usually weak) expres-
sion of CDX2 in approximately 40% of cases [57, 62, 63].While
limited previous studies had only assessed PAX8 expression in
mucinous carcinomas (10/25; 40% expression) [64], a recent
study confirmed expression of PAX8 in MBT (14/23; 61%) as
well as ovarian mucinous carcinomas (11/24; 46%). HER2 over-
expression or amplification has been reported in up to 20% of
MBT [65] and may sometimes be useful in distinguishing pri-
mary frommetastatic ovarian involvement. The proliferative rate
is usually low, andKi67 demonstrates predominant expression in
cells at the base of the papillary structures with decreasing ex-
pression toward their tips.
No unequivocal cases of peritoneal implants associated
with MBT have been reported in the literature, and their oc-
currence should prompt exclusion of secondary ovarian in-
volvement (see below discussion on metastatic disease). The
vast majority of MBTs have an excellent prognosis with over-
all survival approaching 95–100% [5]. A recent single-center
study including 254 patients with stage I BOT found a higher
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incidence of invasive recurrences in MBT compared to SBT
following fertility-conserving surgery. However, possible in-
sufficient sampling is a concern in largeMBT, and this finding
needs to be confirmed in further studies [66]. Histogenetically,
development ofMBT frommature teratoma or via metaplastic
Brenner tumors has been discussed, and ovarian mucinous
and Brenner tumors may share differentiation from a common
stem cell [67, 68, 69, 70]. The most common molecular ge-
netic aberrations are KRAS mutations previously observed in
approximately 60% of MBT, with detection frequencies of up
to 92% by newer targeted deep sequencing approaches
[71–73]. Ovarian mucinous tumors are markedly
Fig. 2 MBT showing cystic glandular structures with papillary
infoldings, columnar cells with abundant cytoplasmic mucin, admixed
with goblet cells of variable degrees of maturation (a) and with basally
located nuclei with no considerable nuclear atypia (b). MBT with
microinvasion is characterized by small cell groups and glands with
cytoplasmic eosinophilia within a normal ovarian stroma without
desmoplastic change (c). MBT with intraepithelial carcinoma is
characterized by focal high-grade nuclear atypia, commonly associated
with more complex epithelial proliferations, next to conventional MBT
structures with sharp transition (d). Mucinous carcinoma with expansile
(“pushing border”) invasion shows confluent glandular and papillary
epithelial proliferations without stromal desmoplasia (e). Mucinous
carcinoma with destructive invasion demonstrates haphazardly
infiltrating glands and is characterized by desmoplastic tumor stroma (f)
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heterogeneous, with frequent co-occurrence of adenomatous,
borderline, and carcinomatous components, suggesting a step-
wise progression in at least part of the cases. Therefore, careful
gross examination and sampling is mandatory and at least one
section per centimeter largest tumor diameter should be exam-
ined, increasing to two blocks per centimeter diameter in mu-
cinous tumors >10 cm [5].
Microinvasion
MBTwith microinvasion is defined by stromal invasion mea-
suring less than 5 mm in the greatest linear dimension and
consisting of single cells, clusters, or small foci of confluent
glandular or cribriform growth, regardless of the number of
microinvasive foci (Fig. 2c). Cases with microinvasive foci
displaying high-grade nuclear atypia should be designated
microinvasive carcinoma according to the recent WHO clas-
sification, although the prognostic value of this category re-
mains to be defined [5, 38]. Microinvasion has been reported
in 4 to 18% of MBT and has no adverse effect on prognosis
[74–76]. Nevertheless, additional sampling as well as immu-
nohistochemical testing are recommended to exclude frankly
invasive carcinoma or metastatic disease.
Intraepithelial carcinoma
MBT with intraepithelial carcinoma has been described in
40 to 55% of MBT and is characterized by areas with
high-grade nuclear atypia that differ cytologically from
the background epithelium, usually with sharp demarca-
tion [74–76] (Fig. 2d). While intraepithelial carcinoma is
often associated with increased architectural complexity
of epithelial stratification or cribriform growth, this crite-
rion is neither necessary nor sufficient, and the diagnosis
of intraepithelial carcinoma should be solely based on
nuclear cytomorphology. Although some studies reported
a higher recurrence risk, most studies observed no differ-
ence in overall survival in cases of MBT with or without
intraepithelial carcinoma [75, 77, 78].
Mural nodules in MBT
A peculiarity of MBT is their occasional association with
so-called mural nodules, comprising either reactive
sarcoma-like nodules or foci of frank sarcoma or anaplas-
tic carcinoma within the cyst wall, varying widely in size
(up to 10 cm) and number. Sarcoma-like mural nodules
Fig. 3 Ovarian metastases mimicking MBT originating from various extra-ovarian primary tumors: metastatic low-grade appendiceal mucinous
neoplasm (a), gastric intestinal type (b), colorectal (c), and pancreatic ductal adenocarcinoma (d)
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have no adverse prognostic impact [5]. A study including
34 patients with mucinous ovarian tumors and nodules of
anaplastic carcinoma found that the presence of anaplastic
nodules in unruptured stage I mucinous tumors did not
carry an adverse prognosis [79]. MBT with anaplastic car-
cinoma should be classified according to its carcinomatous
component.
Differential diagnosis of MBT and mucinous carcinoma
with expansile or destructive invasion
The distinction of MBT from its invasive counterparts, in
particular those with a confluent/expansile growth pattern,
can be challenging and is worth emphasizing here. The exis-
tence of a subgroup of mucinous ovarian neoplasms lacking
Fig. 4 Brenner tumor (a) showing epithelial cell nests of variable size,
with transitional cell-like morphology, embedded in a fibrous stroma. The
epithelium-to-stroma ratio is even. Central cysts are lined by a single layer
of columnar mucinous cells. Metaplastic Brenner tumor (b) demonstrates
a cystic structure with predominance of mucinous epithelium. GATA3 (c)
is diffusely expressed in Brenner tumors, and sometimes many luteinized
stromal cells are present highlighted by calretinin stain (d). Brenner BOT
are characterized by a significantly increased epithelium-to-stroma ratio
(e) but share the same cytological details as benign Brenner tumor (f)
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the criteria for classic destructive stromal invasion but rarely
associated with adverse prognosis and metastasis has long
been recognized. In 1973, Hart and Norris first suggested a
category of “non-invasive mucinous carcinoma” of the ovary
defined by stratification of more than three cell layers and
severe nuclear atypia [80]. The current WHO classification
distinguishes two types of mucinous carcinoma based on their
growth pattern [5]:
Mucinous carcinoma with confluent/expansile invasion is
characterized by a confluent growth pattern, marked epithelial
proliferation with glandular crowding, and solid or cribriform
epithelial sheets with “labyrinthine appearance” obliterating
the cystic spaces. The degree of nuclear atypia is often similar
to MBT, and there is usually a sharp tumor-host interface
without stromal desmoplasia [76]. Prognosis of this tumor
variant, especially when confined to the ovary at presentation,
is very favorable and the overall survival appears to approach
that of MBT [75, 78, 81].
Mucinous carcinoma with destructive infiltrative invasion
is less common and defined by obvious invasive growth with
a haphazard arrangement of infiltrative glands, tubules, or
epithelial cell nests [76]. Associated stromal desmoplasia is
commonly present, but its absence does not exclude the diag-
nosis of infiltrative carcinoma (Fig. 2f). The majority of mu-
cinous carcinomas are diagnosed at an early stage when con-
fined to one ovary (FIGO stage I). Prognosis for stage I dis-
ease is very favorable, though not as good as for expansile
mucinous carcinomas. Primary advanced stage mucinous car-
cinomas are rare, associated with very poor prognosis, and
should prompt exclusion of metastatic disease from an extra-
ovarian primary [82, 83].
Differential diagnosis of MBT and secondary ovarian
involvement by metastatic disease
No single criterion allows definitive differentiation of primary
versus metastatic ovarian mucinous tumors, but by taking into
account combined clinical, histological, and immunohistochem-
ical features, distinction is possible in more than 85% of cases.
Features favoring metastases include smaller size <10 cm,
bilaterality, surface involvement, (multi)nodular growth pattern,
extra-ovarian disease, and associated pseudomyxoma ovarii or
pseudomyxoma peritonei. Cytomorphologic features raising
suspicion for metastasis in cases with typical MBT architecture
include foci of high-grade nuclear atypia, prominent nucleoli,
and significant mitotic activity. In contrast, a primary ovarian
MBT is supported by associated mucinous cystadenofibroma,
Brenner tumor, teratoma, or endometriosis [84–88].
Ovarian metastases with mucinous differentiation arise most
frequently from appendiceal primary tumors, in particular low-
grade appendiceal mucinous neoplasms (LAMN) [86] (Fig.
3a). Consequently, most treatment guidelines recommend rou-
tine appendectomy in cases of MBT or mucinous carcinoma
even if the vermiform appendix appears unremarkable intraop-
eratively. Metastases from appendiceal primaries usually show
diffuse expression of cytokeratin 20, CDX2, and MUC2; vari-
able expression of MUC5AC; and patchy co-expression of
cytokeratin 7 in approximately half of the cases. Most low-
grade appendiceal mucinous neoplasms are associated with
the clinical picture of pseudomyxoma peritonei [57, 67]. In
contrast, only a small percentage of those MBTs arising within
mature cystic teratoma have been unequivocally associated
with pseudomyxoma peritonei [67, 85]. Of note, teratoma-
associated MBT are characterized by an immunohistochemical
expression profile similar to mucinous neoplasms of the lower
gastrointestinal tract, with diffuse expression of cytokeratin 20
and CDX2 and absence of cytokeratin 7 [63, 89, 90].
Intense and diffuse expression of CDX2 should raise sus-
picion for metastasis from a gastrointestinal primary, with the
rare exception of teratoma-associated MBT [63, 89].
The second most common mimics of MBT are metastatic
mucinous carcinomas of pancreatobiliary origin [86] (Fig.
3d), often demonstrating a morphological pattern of small
invasive single cells or glands with marked atypia next to large
cytologically bland cystic structures. Their immunohisto-
chemical expression profile of cytokeratins 7 and 20 and
MUC5AC is comparable to MBT, with additional expression
of cytokeratin 17 and MUC1, as well as expression of
cadherin-17 and loss of DPC4 in about 50% of cases [57,
91, 92]. Negativity of DPC4 excludes an ovarian primary
while expression of PAX-8 strongly favors an ovarian prima-
ry. Of note, a small subset of non-mucinous pancreatic adeno-
carcinomas (1/12; 8%) as well as two out of two
cholangiocarcinomas demonstrated PAX8 expression in a
comprehensive analysis [64, 93].
Further extra-ovarian primaries giving rise to mucinous
ovarian metastases include colorectal (Fig. 3c), gastric (Fig.
3b), breast, and endocervical carcinomas. While the expres-
sion pattern of cytokeratins 7 and 20 is most useful in the
differential of MBT and lower gastrointestinal tract tumors,
with diffuse expression of cytokeratin 20 and absence of
cytokeratin 7 favoring gastrointestinal origin, this panel is
not helpful for distinguishing MBT from upper gastrointesti-
nal tract neoplasms. In contrast, absence of CDX2 strongly
favors primary ovarian origin over both upper and lower gas-
trointestinal tract origins [63, 94]. Additional immunohisto-
chemical markers that have been suggested in this context
include the expression of cadherin-17, racemase, and nuclear
ß-catenin, in the absence of cytokeratin 7 in tumors of gastro-
intestinal origin [57, 92, 95]. Metastases from gastric carcino-
mas can be difficult to prove by immunohistochemistry; ap-
proximately half of the cases demonstrate expression of
cadherin-17, and a quarter express racemase, which is absent
in almost all primary ovarian mucinous tumors [92, 96].
Further potentially useful immunohistochemical markers in-
clude estrogen and progesterone receptors and GATA3 for
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distinction of metastases from breast carcinomas and p16 and
HPV for metastatic cervical adenocarcinomas.
Borderline Brenner tumor
Transitional cell/Brenner tumors of the ovary are generally
rare, and only less than 3–5% are of borderline or invasive
type. To date, approximately 30 borderline Brenner tumors
have been reported in the literature [5, 97].
Borderline Brenner tumors are thought to arise from be-
nign Brenner tumors, as both components often occur to-
gether. Commonly found Walthard cell nests have been
suggested as possible histogenetic origin based on their
shared immunohistochemical expression profile, but are on-
ly infrequently associated with Brenner tumors [68, 98].
Limited data on their molecular characteristics suggested
that loss of CDK2A (gene encoding p16) and somatic mu-
tations in KRAS and PIK3CA may be involved in the pro-
gression from benign to borderline Brenner tumors [99,
100]. Data on their biologic behavior is limited due to the
small number of reported cases. Despite a generally favor-
able prognosis, rare recurrences and deaths have been re-
ported, including one uterine recurrence of a borderline
Brenner tumor harboring an exon 9 PIK3CA mutation [97].
Compared to benign Brenner tumors which are commonly
small (<2 cm) and predominantly solid/fibromatous (Fig. 4a),
borderline Brenner tumors are usually larger than 10 cm
(mean 18 cm) with a predominating epithelial proliferation
(Fig. 4e and f). Cystic areas demonstrate papillary or polypoid
infoldings, covered by a thick layer of transitional-type cells,
resembling non-invasive papillary urothelial carcinomas of
the urinary tract. Mitotic figures may be numerous.
The immunohistochemical expression profile of Brenner
tumors, including benign, borderline, and malignant, overlaps
with urothelial differentiation, with expression of GATA3
(Fig. 4c), cytokeratin 7, and p63; variable expression of
uroplakin and thrombomodulin; and absence of WT1 and es-
trogen and progesterone receptors. Calretinin may highlight
luteinized stromal cells. (Fig. 4d) In contrast to urothelial dif-
ferentiation, cytokeratin 20 is usually absent [98, 101].
An important differential diagnosis of borderline Brenner
tumor is (benign) metaplastic Brenner tumors, where the solid
transitional cell nests are replaced by mucinous differentiation
(often expressing cytokeratin 20) with a central cystic cavity
(Fig. 4b) and sometimes associated with complex glandular
proliferations [102]. As mentioned above, it is possible that
such biphasic mucinous-transitional cell neoplasms may rep-
resent divergent differentiation from a common stem cell.
Malignant Brenner tumors of the ovary are by definition as-
sociated with a benign or borderline Brenner tumor and dis-
tinguished by an invasive component usually resembling
high-grade invasive urothelial carcinoma. In the differential
diagnosis with metastatic urothelial carcinoma of the urinary
tract, the detection of an associated benign Brenner tumor
component, as well as expression of CA125 and absence of
cytokeratin 20, may be helpful to confirm a borderline
Brenner tumor of primary ovarian origin.
Borderline ovarian tumors related to ovarian
endometriosis
Endometriosis affects 6–10% of reproductive-age women and
has been associated with specific molecular and developmen-
tal abnormalities that allow endometrial cells to grow outside
of the uterus following menstrual efflux, epithelial metaplasia,
or differentiation of stem cells [103, 104]. Endometriosis can
be separated into superficial peritoneal and deep infiltrating
subgroups. Ovarian endometriosis and in particular ovarian
endometriotic cysts represent examples of the second group
and have been shown to be clonal lesions by many but not all
investigators [105]. Endometriotic cysts have also been asso-
ciated with increased levels of oxidative stress and reactive
oxygen detoxification pathway intermediates, specific cytoge-
netic abnormalities, loss of PTEN and ARID1A expression,
microsatellite instability, let-7 microRNA-dysregulated over-
expression of KRAS, and significant epithelial atypia (seen in
8% of cases) [105–109]. The last feature, known as atypical
endometriosis, is frequently seen adjacent to endometriosis-
associated carcinomas and BOT as detailed below [110].
Seromucinous borderline tumor
Seromucinous borderline tumor (SMBT), also known as atyp-
ical proliferative seromucinous tumor, formerly endocervical-
type mucinous BOT, or mullerian mucinous BOT, accounts
for approximately 5–7% of all BOT. Although long recog-
nized under a variety of names, these tumors are now formally
established as a separate category in the revised 2014 WHO
Classification of Tumours of the Female Genital Organs. Of
note, the term mullerian mucinous BOT or mixed mullerian
BOT is more recently being favored by some pathologists as it
reflects the mullerian differentiation of these tumors [111].
Unlike the other endometriosis-associated BOT (discussed
below), SMBT is the most common type of tumor within its
category far exceeding benign seromucinous tumors
(cystadenoma and adenofibroma) and seromucinous carcino-
mas [112]. SMBTs usually arise in young women (34–44 years
old) and present as unilocular or paucilocular cysts averaging
8–10 cm in diameter often with intracystic papillae [113, 114].
Bilateral involvement is seen in 40%, and up to 20% have
peritoneal implants or lymph node involvement. Associated
endometriosis is seen in 30–70% of cases, and SMBT often
co-exists with endometriosis-related cancers, most commonly
of endometrioid histology, so extensive sectioning is indicated.
It has been proposed that SMBTs usually arise within atypical
endometriotic cysts that undergo mucinous differentiation. As
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in other endometriosis-related BOT, loss of ARID1A expres-
sion is common and mutations have been documented in 33%
of cases [115, 116]. Similar to other mucinous female genital
tract tumors, KRAS mutations are frequent, being detected in
69% of cases [117]. Histologically, SMBTs have architectural
features similar to SBTs (Fig. 5a). However, the branching pa-
pillae in SMBTs are lined by varying proportions of
endocervical-type mucinous, tubal-type serous, endometrioid,
and indeterminate cells with dense eosinophilic cytoplasm.
Hobnail or clear cells and prominent squamous metaplasia
may also be seen. The presence of at least two different types
of mullerian differentiation is required for the diagnosis [5].
Virtually all cases are associated with a significant amount of
acute inflammation, edema, and occasional eosinophils which
can be diagnostically useful (Fig. 5b). Unlike most other BOT,
the majority of cases do stain positively for vimentin. Estrogen
and progesterone receptors are generally positive (Fig. 5c), and
WT1 (Fig. 5d), CK20, and CDX2 are negative. Diffuse cyto-
plasmic expression of MUC5AC is seen in the endocervical-
type mucinous component [59, 60, 118]. Microinvasion and
intraepithelial carcinoma may be seen and are defined in the
same way as in other BOT (see above). Peritoneal implants
associated with SMBT have been infrequently reported. Most
cases have a good outcome, even in the presence of
extraovarian disease. Destructive stromal invasion of 5 mm or
more, complex expansile growth, and/or invasive extraovarian
disease are the standard criteria defining progression to
seromucinous carcinoma [112].
Fig. 5 SMBT demonstrating a
papillary architecture with
hierarchical branching (a). The
epithelium is columnar with focal
multilayering with papillary and
pseudopapillary infoldings and
variable cytoplasmic mucin
content. Stroma and epithelium
show infiltration by neutrophils
(b). Immunohistochemical
expression of ER (and/or PR) (c)
and absence of WT1 (d) is typical
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Fig. 6 EBT of adenofibromatous type with endometrioid glandular
proliferations embedded in a fibroblastic stroma (a) with some
epithelial cell nests consisting of a central squamous area (b). Glandular
proliferations express CK7 (c) and ER (e). CK 8/18 is diffusely expressed
(d) whereas the squamous areas are CK5/6-positive (f) and do also
express CDX2 (not shown). Endometrioid cystadenofibroma (g) is
characterized by round and cystic glands, evenly distributed in a
fibroblastic stroma. Cystic/villoglandular EBTs (h) share the same
architecture as SBTs but differ in their endometrioid cytology
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Endometrioid borderline tumor
Endometrioid borderline tumor (EBT), also known as
atypical proliferative endometrioid tumor, accounts for
2–3% of BOT [119, 120]. Mean age at diagnosis is
57 years. Co-existing endometriosis is seen in 63% of
cases, and 39% have synchronous hyperplasia or carcino-
ma in the endometrium. Therefore, endometrial curettage
is recommended in case of fertility preserving therapy.
ARID1A mutations are detected in 40% of cases [115].
KRAS mutations are found in 29% of cases with associ-
ated endometriosis, but are rare in the remainder [121].
Abnormalities in the Wnt/beta-catenin and PI3K/mTOR
pathways are also common. Average tumor diameter is
9 cm with two thirds of cases having a cystic component
and the remainder being predominantly solid. An adjacent
benign endometrioid adenofibroma is observed in 50% of
cases. Bilaterality is seen in 4% of cases. Histologically,
tumors can show two patterns, adenofibromatous or
villoglandular. Both subtypes may show focal areas of
cribiform growth, squamous morules, and intermixed ne-
crotic debris. In the adenofibromatous subgroup, distinc-
tion from adenofibroma is made on the basis of a complex
hyperplastic epithelial growth pattern with or without mild
to moderate nuclear atypia (Fig. 6a and b). Villoglandular
EBT may occasionally demonstrate an architecture similar
to SBT but differ in their cytologic features (Fig. 6h). The
cells are more cylindrical with oval nuclei orientated per-
pendicular to the basement membrane. Sometimes, this
can be ambiguous and there may be overlap with serous
differentiation. Immunohistochemical stains (Fig. 6c to f)
are not usually necessary to differentiate EBT from SBT.
Fig. 7 CCBT demonstrating variably sized glands lined by clear cells,
evenly spaced with focal glandular crowding, and embedded in a
fibromatous stroma (a), with mild to moderate nuclear atypia (b). In
contrast, intracystic clear cell carcinoma demonstrates intracystic
papillary proliferations lined by clear and hobnail cells (c) with high-
grade nuclear atypia and prominent nucleoli (d)
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However, WT1 is usually negative in contrast to SBT,
while focal p16 staining may be seen in up to 50% of
EBT [122]. Intraepithelial carcinoma (severe nuclear
atypia) and microinvasion follow the same criteria as in
MBT, but have little or no prognostic significance.
Peri toneal implants are exceedingly rare [119] .
Progression to carcinoma is defined by a confluent
expansile growth and/or one or more foci of destructive
invasion of ≥5 mm. In view of its rarity, absence of
extraovarian disease, and the lack of any well-
documented malignant behavior, the diagnosis of EBT
currently has few if any implications for clinical manage-
ment [123].
Mimics of EBT include metastases from gastrointestinal,
endocervical, or endometrial adenocarcinomas. Positivity of
PAX8 and estrogen receptor distinguish EBT from gastroin-
testinal carcinoma. Diffuse and strong nuclear p16 expression
and detection of HPV-DNA may be helpful for the differenti-
ation between EBT and metastasis of HPV-related
endocervical adenocarcinoma. MUC4 and HIK1083 can be
useful for distinguishing HPV-negative endocervical adeno-
carcinomas of gastric type. Metastases from well-
differentiated endometrial carcinomas demonstrate a similar
immunohistochemical expression pattern as EBT.
Clear cell borderline tumor
Clear cell borderline tumor (CCBT), also known as atypical
proliferative clear cell tumor, represents less than 1% of all
BOT [5, 124, 125]. It usually occurs between 59 and
68 years of age. Tumors average 6 cm in diameter and
are generally unilateral. The majority have a solid appear-
ance with small cysts (“swiss cheese” pattern), similar to
clear cell adenofibroma but with some softer, fleshier areas.
A minority arise within atypical endometriotic cysts.
CCBTs are highly likely to be associated with foci of frank
clear cell carcinoma, so extensive sectioning, preferably
submitting the entire specimen, is recommended. Given
its rarity, few specific molecular studies have been conduct-
ed, but there is a strong association with endometriosis,
often atypical [110]. When seen adjacent to clear cell car-
cinoma, a shared loss of ARID1A expression suggests a
clonal relationship [126]. The frequency of PIK3CA muta-
tions, an early event in clear cell carcinoma, has not been
studied in adenofibromatous-type CCBT. Histologically,
CCBTs are characterized by round to oval evenly spaced
glands embedded in an adenofibromatous-type stroma
(Fig. 7a). Compared with clear cell adenofibroma, there is
more glandular crowding and proliferation. Glands are
lined by flat, cuboidal, or hobnail cells with moderate nu-
clear atypia (Fig. 7b), small nucleoli, and coarse chromatin
clumping. Mitotic rate should be less than four per high
power field. The key discriminating feature is the degree
of nuclear atypia. Low-grade atypia characterizes adenomas
whereas an intermediate nuclear grade defines the border-
line category. Clear cell carcinoma is characterized by at
least focal high-grade nuclear atypia with prominent nucle-
oli (Fig. 7d), commonly in a background of intermediate
nuclear atypia, and often associated with hyalinized stroma
[127]. However, nuclear grading is highly subjective and
diagnosis should err on the side of malignancy, particularly
in the tubulocystic variant which can often appear decep-
tively bland. Similarly, a purely cystic growth pattern is
very unusual in CCBT and should raise suspicion for the
intracystic variant of clear cell carcinoma (Fig. 7c).
Immunostains for HNF1 and Napsin A (usually positive)
and WT1 and estrogen and progesterone receptors (usually
negative) may be helpful to establish clear cell differentia-
tion in some cases. Microinvasion is defined similarly to
other BOT (<5 mm). Although it has been stated that
CCBT may show intraepithelial carcinoma, this diagnosis
should be made with great discretion in view of the fre-
quency of co-existent clear cell carcinoma. All CCBTs
followed thus far have acted in a benign fashion.
However, there is no data regarding the prognosis of cases
with either intraepithelial carcinoma or microinvasion.
Conclusion and perspective
In line with our evolving understanding that different ovarian
cancer histotypes represent distinct disease entities, emerging
knowledge suggests that subtypes of borderline ovarian tu-
mors likewise comprise distinct biologic, pathogenetic, and
molecular entities [17, 128] precluding a single unifying con-
cept for BOT. The borderline malignant potential is best val-
idated for SBTwhich share molecular and genetic alterations
with low-grade serous carcinomas and can present at higher
stages with peritoneal implants and/or lymph node involve-
ment. In addition, recurrences occur in a small percentage of
SBT with occasional malignant transformation. On the other
hand, non-serous subtypes of BOTcommonly present at stage
I confined to the ovary(ies) and are associated with an overall
survival approaching that of the general population in well-
sampled tumors.
Although a workshop sponsored by the NIH in 2003
provided consensus for many of the currently accepted
diagnostic criteria of BOT [6], some challenges remain,
e.g., distinction of MBT from expansile mucinous carci-
noma or differentiation of SBT with microinvasion versus
small foci of low-grade serous carcinoma. One of the
most important changes of the current WHO 2014 classi-
fication is the new terminology of non-invasive implants
associated with SBT, whereas any invasive foci (prior
invasive implants) are now considered peritoneal LGSC
more in line with their biological behavior.
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Ongoing controversies include the terminology of non-
serous borderline tumors as some pathologists prefer the
term “atypical proliferative tumor” in view of their largely
benign behavior. The concepts of intraepithelial carcinoma
and microinvasion may evolve in the future as their pres-
ence appears to have no prognostic impact and is subject
to considerable inter-observer variability.
Future studies such as large multicenter trials with associ-
ated molecular analyses should address these controversies
and aim to identify reliable risk factors for recurrence or ma-
lignant transformation of SBT.
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